• 1:中国医师协会心血管内科医师分会结构性心脏病专业委员会

摘要(Abstract)：

<正>心房颤动(atrial fibrillation,AF)是临床最常见的心律失常之一,AF可致左心耳(left atrial appendage,LAA)内血栓形成,而血栓脱落可致血栓栓塞性疾病。Framingham研究~([1])表明,AF与卒中事件有显著相关性。长期口服抗凝药物是预防栓塞的主要方法,但因其存在一定的出血风险,受药物、食物等因素影响较多,患者长期服药依从性较差,临床应用受限。外科切除LAA可以降低卒中风险~([2])。Madden手术切除了2例患者的LAA,以预防卒中复发,引起了临床医师对干预LAA的

关键词(KeyWords)： 左心耳;封堵术;临床路径;共识

Abstract:

Keywords:

基金项目(Foundation):

作者(Author):

参考文献(References)：

• [1] Wolf PA, Kannel WB, McGee DL, et al. Duration of atrialfibrillation andimminence of stroke:the Framingham study. Stroke,1983,14(5):664-667.
• [2] Cox JL, Ad N, Palazzo T. Impact of the maze procedure on the stroke rate in patients with atrial fibrillation. J Thorac Cardiovasc Surg,1999,118(5):833-840.
• [3] Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke:results from the national registry of atrialfibrillation. JAMA, 2001,285(22):2864-2870.
• [4] Aberg H. Atrialfibrillation. I. A study of atrial thrombosis and systemic embolism in a necropsy material. Acta Med Scand,1969,185(5):373-379.
• [5] Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrialfibrillation. Ann Thorac Surg, 1996,61(2):755-759.
• [6]中华医学会心电生理和起搏分会，中国医师协会心律学专业委员会心房颤动防治专家工作委员会.心房颤动：目前的认识和建议2015.中华心律失常学杂志，2015,19(5):321-384.
• [7] Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J,2016,37(38):2893-2962.
• [8] Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation:a randomised non-inferiority trial.Lancet,2009,374(9689):534-542.
• [9] Reddy VY, Holmes D, Doshi SK, et al. Safety of percutaneous left atrial appendage closure:results from the Watchman left atrial appendage system for embolic protection in patients with AF(PROTECT AF)clinical trial and the continued access registry. Circulation,2011,123(4):417-424.
• [10] Reddy VY, Doshi SK, Sievert H, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrialfibrillation:2.3-Year Follow-up of the PROTECT AF(Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation)Trial.Circulation,2013,127(6):720-729.
• [11] Alli O, Doshi S, Kar S, et al. Quality of life assessment in the randomized PROTECT AF(Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation)trial of patients at risk for stroke with nonvalvular atrial fibrillation. J Am Coll Cardiol, 2013,61(17):1790-1798.
• [12] Holmes DR Jr, Doshi SK, Kar S, et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrialfibrillation:a patient-level meta-analysis. J Am Coll Cardiol,2015,65(24):2614-2623.
• [13] January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation,2019,140(2):e125-e151.
• [14] Sick PB, Schuler G, Hauptmann KE, et al. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrialfibrillation. J Am Coll Cardiol, 2007,49(13):1490-1495.
• [15] Reddy VY, M?bius-Winkler S, Miller MA, et al. Left atrial appendage closure with the watchman device in patients with a contraindication for oral anticoagulation:The ASAP Study(ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol, 2013,61(25):2551-2556.
• [16] Boersma LV, Schmidt B, Betts TR, et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device:periprocedural outcomes from the EWOLUTION registry. Eur Heart J,2016,37(31):2465-2474.
• [17] Boersma LV, Ince H, Kische S, et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or withnot contraindication to oral anticoagulation:1-Year follow-up outcome date of the EWOLUTION trial. Heart Rhythm,2017, 14(9):1302-1308.
• [18] Kodali S, Thourani VH, White J, et al. Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable, high-risk and intermediate-risk patients with aortic stenosis. Eur Heart J,2016,37(28):2252-2262.
• [19] Korsholm K,Jensen JM,Nielsen-Kudsk JE. Intracardiac echocardiography from the left atrium for procedural guidance of transcatheter left atrial appendage occlusion. JACC:Cardiovasc Interv, 2017, 10(21):2198-2206.
• [20] Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrialfibrillation.Eur Heart J,2018,39(16):1330-1393.
• [21] Ostermayer SH, Reisman M, Kramer PH, et al.Percutaneous left atrial appendage transcatheter occlusion(PLAATO system)to prevent stroke in high-risk patients with non-rheumatic atrialfibrillationresults from the international multi-center feasibility trials.J Am Coll Cardiol,2005,46(1):9-14.
• [22] Almutairi AR, Zhou L, Gellad WF, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants for atrialfibrillation and venous thromboembolism:A systematic review and Meta-analyses. Clin Ther,2017,39(7):1456-1478.e36.
• [23] Ueberham L, Dagres N, Potpara TS, et al. Pharmacological and non-pharmacological treatments for stroke prevention in patients with atrialfibrillation. Adv Ther,2017,34(10):2274-2294.
• [24] Waksman R, Pendyala LK. Overview of the Food and Drug Administration circulatory system devices panel meetings on WATCHMAN left atrial appendage closure therapy. Am J Cardiol,2015,115(3):378-384.
• [25] Reddy VY, Gibson DN, Kar S, et al. Post-approval U.S. experience with left atrial appendage closure for stroke prevention in atrialfibrillation. J Am Coll Cardiol, 2017,69(3):253-261.
• [26] Hornung M, Gafoor S, Id D,et al. Catheter-based closure of residual leaks after percutaneous occlusion of the left atrial appendage. Catheter Cardiovasc Interv, 2016,87(7):1324-1330.
• [27] Calvo N, Salterain N, Arguedas H, et al. Combined catheter ablation and left atrial appendage closure as a hybrid procedure for the treatment of atrialfibrillation. Europace, 2015,17(10):1533-1540.
• [28] Walker DT, Phillips KP. Left atrial catheter ablation subsequent to Watchman(R)left atrial appendage device implantation:a single centre experience. Europace, 2015,17(9):1402-1406.
• [29] Fassini G, Conti S, Moltrasio M,et al. Concomitant cryoballoon ablation and percutaneous closure of left atrial appendage in patients with atrialfibrillation. Europace, 2016,18(11):1705-1710.
• [30] Phillips KP, Walker DT, Humphries JA. Combined catheter ablation for atrialfibrillation and Watchman(R)left atrial appendage occlusion procedures:Five-year experience. J Arrhythm, 2016,32(2):119-126.
• [31] Wintgens L, Romanov A, Phillips K, et al. Combined atrial fibrillation ablation and left atrial appendage closure:long-term follow-up from a large multicentre registry. Europace, 2018,20(11):1783-1789.